Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Remission versus response as the goal of therapy in ADHD: a new standard for the field?

Steele M, Jensen PS, Quinn DM.

Clin Ther. 2006 Nov;28(11):1892-908. Review.

PMID:
17213010
2.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
3.

Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.

Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gómez N, Yelmo S, Ferrer M, Martínez Y, Casas M.

CNS Drugs. 2008;22(7):603-11.

PMID:
18547128
4.

A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.

Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.

Can J Clin Pharmacol. 2006 Winter;13(1):e50-62. Epub 2006 Jan 23.

5.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
6.

Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.

Christman AK, Fermo JD, Markowitz JS.

Pharmacotherapy. 2004 Aug;24(8):1020-36. Review.

PMID:
15338851
7.

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.

J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce.

PMID:
19440077
8.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
10.

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK.

Biol Psychiatry. 2008 May 15;63(10):981-9. doi: 10.1016/j.biopsych.2007.11.008. Epub 2008 Jan 22.

PMID:
18206857
11.
12.

Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.

Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS.

J Clin Psychiatry. 2008 Dec;69(12):1938-47. Epub 2008 Dec 2.

PMID:
19192455
13.

National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.

Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tzang RF, Wu YY, Huang YF, Chou MC, Liang HY, Hsu YC, Lu HH, Huang YS.

J Clin Psychiatry. 2008 Jan;69(1):131-40.

PMID:
18312048
14.

Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.

Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.

Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x.

15.

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.

Rösler M, Fischer R, Ammer R, Ose C, Retz W.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9. doi: 10.1007/s00406-008-0845-4. Epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):368.

PMID:
19165529
16.

[Methylphenidate in the treatment of attention-deficit/hyperactivity disorder: are we achieving an adequate clinical practice?].

Gonzalez de Dios J, Cardó E, Servera M.

Rev Neurol. 2006 Dec 16-31;43(12):705-14. Review. Spanish.

17.

OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.

Ramos-Quiroga JA, Corominas M, Castells X, Bosch R, Casas M.

Expert Rev Neurother. 2009 Aug;9(8):1121-31. doi: 10.1586/ern.09.65. Review.

PMID:
19673602
18.
19.
20.

A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.

Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD.

J Clin Psychiatry. 2008 Jan;69(1):149-59. Erratum in: J Clin Psychiatry. 2008 Feb;69(2):329.

PMID:
18312050
Items per page

Supplemental Content

Write to the Help Desk